The post Policy wins and the X waiver: MHA recaps the 117th congressional session appeared first on Mental Health America.
3 common myths about workplace mental health and wellness
The post 3 common myths about workplace mental health and wellness appeared first on Mental Health America.
10 Young Adults Transforming Mental Health
The post 10 Young Adults Transforming Mental Health appeared first on Mental Health America.
STAT+: In the battle of sepsis algorithms, performance alone doesn’t predict victory
Five years ago, the bottom fell out of sepsis prediction software. Hundreds of hospitals had adopted an algorithm from electronic health record company Epic that promised to alert physicians to predicted cases of sepsis, a life-threatening reaction to infection that kills more than 350,000 people in the United States every year.
The AI was a technical flop. Despite its results on paper, the technology failed to perform in the real world, and sent so many alerts that doctors tuned them out or hospitals turned them off.
Half a decade on, new sepsis models are hitting the scene. Epic released a retooled version of its own algorithm. Startups are testing their models in health systems. A team uses large language models to mine clinical notes for signs of sepsis. And on Tuesday, a sepsis flagging device from Bayesian Health, with origins at Johns Hopkins, announced it has received clearance from the Food and Drug Administration.
PCOS’s new name is PMOS, a small letter change that required a big scientific process
PCOS is dead. Long live PMOS.
Revealed Tuesday, the one-letter change in nomenclature for a common metabolic condition in women may seem unremarkable, but it follows more than a decade of vigorous debate over the need for a name that more precisely and completely describes what until now was known as polycystic ovary syndrome (PCOS).
Opinion: STAT+: Pharma and biotech leaders are destroying their own industry
In early 2025, biotech experienced a “DeepSeek moment” when biotech and pharma leaders alike realized how quickly China was gaining ground with innovation, speed of drug development, and share of licensing deals. In 2020, global pharmaceutical companies spent about $9 billion on licensed drug assets from China. In 2025, that number shot to more than $137 billion. The first two months of 2026 alone accounted for nearly $50 billion in deals. As a December 2025 report from the National Security Commission on Emerging Biotechnology put it, “in just three years, China’s biopharmaceutical industry rose from near irrelevance to dominance.”
China’s rise is happening with the blessing of U.S. pharmaceutical executives, who are allowing their own industry to be destroyed.
I am a co-chair of a working group at the Council on Foreign Relations investigating the U.S.’s generic pharmaceutical dependence on China. An estimated 60% of our generic medications have an active ingredient that originates in China; some estimates have this figure as high as 80-90%. (The exact percentage is unknown because the Food and Drug Administration doesn’t formally track this information, and because a significant percentage of our drugs are imported from India, which in turn imports chemical precursors from China.)
STAT+: Patients jockey for exemptions from Medicaid’s new work requirements
WASHINGTON — Patient groups are jockeying for exemptions from Medicaid work requirements, but the unusually fast implementation timeline for states is causing headaches.
Federal officials have until June 1 to tell states how to implement a provision of President Trump’s tax cut bill that requires certain Medicaid beneficiaries to show that they’re working, in school, or volunteering in order to keep their coverage. Once that regulation is out, states will have to put their systems in place by Jan. 1.
Advocates for people with certain diseases have been meeting with federal officials to urge that those patients be automatically exempt from the work requirements. For example, Patients with sickle cell disease recently met with White House budget officials to request an exemption. Advocacy groups for people with HIV are making a similar push.
GPs and hospitals to share patient data for single patient record
NHS hospitals and GP practices will be required to share patient data under new government legislation to create a single patient record.
A global matching model of choice and response times in the Deese–Roediger–Mcdermott semantic and structural false recognition paradigms.
Psychological Review, Vol 133(4), Jul 2026, 771-819; doi:10.1037/rev0000596
One of the most common method of eliciting false memories in the laboratory is the Deese–Roediger–McDermott paradigm (Deese, 1959; Roediger & McDermott, 1995), where participants study a set of items that are all similar to a nonpresented critical lure. A common finding is that false recognition to critical lures is much higher than to other nonpresented items and in some cases is even comparable to true recognition, regardless of whether similarity is semantic or structural (e.g., phonological or orthographic) relations. While there exists a handful of computational models of this paradigm, they have only been applied to semantic but not structural false recognition, they have not been fit at the level of individual participants, and they have not been applied to response times. We present a global matching model that addresses all three of these current gaps. Global similarity of semantic and structural representations drives a pair of linear ballistic accumulators, which are used to produce decisions as well as complete response time distributions. In addition to being able to account for heightened false recognition of critical lures, the model was able to account for differences across both individual participants and items, lower correlations between semantic and structural false recognition than true recognition, differences in false recognition across levels of processing, improved true recognition but not false recognition with higher study time, and heightened false recognition under speed emphasis. The model suggests that semantic and structural false recognition can be explained using only a single retrieval mechanism. (PsycInfo Database Record (c) 2026 APA, all rights reserved)
Within-alternative processing supports transitivity of preferences in multiattribute choice.
Psychological Review, Vol 133(4), Jul 2026, 820-845; doi:10.1037/rev0000587
Transitivity of preference (ToP) is a central axiom of rational choice theory. While violating ToP is rare and subject to debate, there have been reports of such violations (Tsetsos et al., 2016a; Tversky, 1969, but see Iverson & Falmagne, 1985; Regenwetter et al., 2011). If humans indeed violate ToP, an important challenge is understanding the conditions and mechanisms that promote either transitive or intransitive preferences. Here, we report the presence of ToP violations using a data analysis method that was prescribed as statistically adequate (Regenwetter et al., 2011), and an experimental design where each choice is presented on a single visual display to avoid artifacts that can be associated with sequential presentation and aggregation across choice stimuli. We introduce two cognitive heuristics that predict certain violations of ToP and we translate them into probabilistic choice models. Then, in three experiments (one of which is a preregistered replication), we evaluate violations of ToP and we assess the models that predict such violations. We find that, despite pervasive individual differences, the ToP adherence rate is much enhanced when the task was presented in a fashion that facilitates within-alternative integration. We also find that the proposed heuristic models successfully explain those ToP violations that do occur. These findings shed light on the conditions and cognitive mechanisms that support ToP. (PsycInfo Database Record (c) 2026 APA, all rights reserved)